Amazing?It's a Phase 2 trial, interim analysis
Efficacy
Injection-Free Rates: A significant portion of patients remained injection-free over the 26-week period, highlighting the potential of Ixo-vec to reduce the treatment burden associated with frequent ocular injections.
Visual Acuity: Patients maintained stable visual acuity, suggesting that Ixo-vec effectively controls the progression of wet AMD.
Where is the improved vision outcome? Without this how can it hold best-in-class treatment for wet AMD ?
Sozinibercept has the potential to improve vision for millions of patients with wet AMD.
If successful OPT could be heading towards new standard of care with best-in-class, is it not?
Amazing? It's a Phase 2 trial, interim...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
49.0¢ |
Change
0.040(8.89%) |
Mkt cap ! $603.2M | |||
| Open | High | Low | Value | Volume |
| 46.0¢ | 49.0¢ | 45.5¢ | $3.430M | 7.316M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7000 | 48.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 49.0¢ | 156010 | 6 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| OPT (ASX) Chart |